International AMR Action! 21 Sep Wellcome Trust-UNGA event / 12-13 Oct Call to Action (Berlin)

Dear All: 

The international conversation continues apace following the recent DRIVE-AB meeting on antibiotic incentives. There are two further important meetings coming up that you may wish to know about.

First, Wellcome Trust is co-hosting a side-event with the UN Foundation during the UN General Assembly on 21 Sep (yes, this week!). The side event is from 8a-10a in New York City. Here is the registration link should you be in NYC on Thursday and able to attend. Panel discussions will focus on the challenges of developing multi-sectoral national action plans as well as covering progress on support mechanisms for antibiotic discovery. The keynote speakers look wonderful, including opening comments from the WHO’s DG:

  • Session title: One Year On: Progress, Challenges, Opportunities, and New Ways of Working to Tackle Antimicrobial Resistance (AMR)
  • Keynote: Dr. Tedros Adhanom Ghebreyesus; Director-General, World Health Organization; Co-Chair, UN Interagency Coordination Group on AMR
  • Keynote: Professor Dame Sally Davies; Chief Medical Officer, United Kingdom; Co-Convener, UN Interagency Coordination Group
  • Keynote: Ms. Maria Helena Semedo; Deputy Director-General, Food and Agriculture Organization of the United Nations
  • Closing: Honorable Dr. Aaron Motsoaledi; Minister of Health, South Africa

Second, Wellcome Trust is also organizing an AMR Call to Action Conference 12-13 October in Berlin. The event is “… an opportunity for national governments and multilateral institutions to come together with the civil society, private and philanthropic sectors to focus on the most critical gaps in tackling the development and spread of drug-resistant infections, and to commit to concerted and tangible actions.” If you think you might be interested in attending (it is invitation-only but I am told there is still some scope to add attendees), please contact Wellcome Trust by email at amrcalltoaction@wellcome.ac.uk.

It is fabulous to see these conversations at the political level … I know that we don’t yet have all the tools we need to ensure a vibrant antibiotic pipeline, but these conversations are the necessary prelude!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

17 April 2023: FREE Masterclass from FDA / CARB-X wants you!

Dear All, Two quick items today. First, FDA have announced an Antimicrobial Drugs Advisory Committee on 17 April 2023 (9a-4.30p ET). The committee will “discuss new drug application (NDA) 216974, for sulbactam-durlobactam for injection, submitted by Entasis Therapeutics, Inc. The Applicant’s proposed indication is for the treatment of infections due to Acinetobacter baumannii-calcoaceticus complex including multidrug-resistant and

WHO 2023 Pipeline Update: Share Your Preclinical Antibacterial Projects!

Dear All, As you know, WHO updates their preclinical and clinical pipeline summaries at regular intervals. The most current reviews are summarized on https://amr.solutions/pathogens-and-pipelines/. These excellent summaries are invaluable for researchers of all types and are also used to inform policy work. There is now a call to for current information on antibacterial pre-clinical projects. Go here

PASTEUR: Sign a letter to make it happen this year!

Dear All, As all regular readers of this newsletter know, I think that creation of suitable Pull incentives by passage of the PASTEUR Act in the United States is THE key to building a vibrant pipeline of products to address the international problem of AMR. PASTEUR came very close to passage at the end of 2022 …

Scroll to Top